Document is current
Any future updates will be listed below
-
Authors
Esposito, Daniela
Ascione, Claudia Maria
Belli, Stefania
Napolitano, Fabiana
Servetto, Alberto
Pepe, Felice
Malapelle, Umberto
Iaccarino, Antonino
Troncone, Giancarlo
Barone, Diletta
Bria, Emilio
Ferrara, Roberto
Lorenzini, Daniele
Lo Russo, Giuseppe
Ghigna, Maria Rosa
Marinello, Arianna
Aldea, Mihaela
Besse, Benjamin
Formisano, Luigi
Bianco, Roberto
-
Funding
Funding for this research was provided by:
Associazione Italiana per la Ricerca sul Cancro (IG 21339, MFAG 21505 - 2018, MFAG 27826-2022, IG20583, Fellowship for Italy 2021 - 26795)
Ministero dell'Università e della Ricerca (PRIN_PNRR-2022-R-BIANCO – MUR 000015, PNC00001)
Ministero della Salute (Ricerca Corrente 2023)
Università Cattolica del Sacro Cuore (UCSC‐Project D1)
- License Information
-
More Information
Article History
Received: 10 September 2024
Accepted: 11 April 2025
First Online: 22 May 2025
Declarations
:
: This study was reviewed and approved by the Federico II University Ethics Committee (ref n 139/22). Participants gave informed consent to participate in the study before taking part. The animal study was performed in accordance with institutional guidelines of the University of Naples Animal Care Committee and in accordance with the Declaration of Helsinki.
: Not Applicable.
: Formisano declares the following competing interests: Consultant and advisory board for Seagen, Amgen, BMS, MSD, Jansen, and Pierre Fabre Pharma. Bianco declares the following competing interests: consultant and advisory board for BMS, MSD, Pfizer, AstraZeneca, Lilly and Novartis. Servetto reports honoraria from Eli Lilly, MSD, and Janssen and travel support from Bristol-Myers Squibb and AstraZeneca. Giuseppe Lo Russo declares advisory boards, consultancies, travel accommodations, speaker fees, writing fees, pi role in profit trials: MSD, Regeneron, Roche, Lilly, BMS, Amgen, AstraZeneca, Johnson And Johnson, Merck, Novartis, Pierre Fabre, Bayer, Beigene, Pfizer, Takeda, GSK, Daiichi,Sanofi, Gilead. Besse reports sponsored research at Gustave Roussy Cancer Center from AbbVie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, Bristol-Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Ignyta, IPSEN, Merck KGaA, Merck Sharp & Dohme, Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, Spectrum Pharmaceuticals, Takeda, and Tiziana Pharma and investigators or coinvestigators of trials for Nerviano, GlaxoSmithKline, Pfizer, Roche-Genentech, Eli Lilly, OSE Pharma, Merck Sharp & Dohme, Celgene, Stemcentrx, Ignyta, AbbVie, Loxo Oncology, AstraZeneca, and Blueprint Medicines. Aldea reports receiving expenses and research funding from Sandoz and research funding from Amgen and AstraZeneca. Marinello declares travel/accommodation from Daiichi Sankyo and not financial support from MSD. The remaining authors declare that they have no competing interests.
